ARKG250516C23000
- 0.03
- -0.06-66.67%
ARK Genomic Revolution ETF Newsroom
Schrödinger To Present Phase 1 Clinical Data On MALT1 Inhibitor SGR-1505 At EHA Annual Congress And International Conference On Malignant Lymphoma
Cathie Wood Dumps Palantir As Stock Touches Peak Prices, Bails On Soaring Flying-Taxi Maker Archer Aviation
Here's How Much $100 Invested In Natera 5 Years Ago Would Be Worth Today
Trump Says 'GREAT PROGRESS MADE' at U.S.-China Trade Talks, Which Will Resume Sunday
10 Health Care Stocks With Whale Alerts In Today's Session
Tempus AI Analyst Ratings
8 Analysts Have This To Say About Natera
Natera Analyst Ratings
Natera Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Raised Its FY25 Sales Guidance Above Estimates.
Natera GAAP EPS of -$0.50 Beats by $0.12, Revenue of $501.8M Beats by $55.13M
Trending Industry Today: ARK Genomic Revolution ETF Leads Gains In ARK ETFs Stocks
Tempus AI Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Results and Raised Its FY25 Sales Guidance.
CRISPR Therapeutics Analyst Ratings
Natera To Present Multiple Datasets In Breast Cancer Together With Collaborators At 2025 ESMO Breast Cancer Annual Congress In Munich
Twist Bioscience And Ginkgo Bioworks Announces Revision In Its Three-Year $15M Collaboration Including Ginkgo Receiving Preferential Pricing With No Required Minimum Purchase Volume
Breaking Down Veracyte: 7 Analysts Share Their Views
Needham Maintains Buy on Veracyte, Lowers Price Target to $41
Veracyte Analyst Ratings
Veracyte Projects Strong Decipher and Afirma Growth, Targets 22.5% Adjusted EBITDA Margin for 2025
Cathie Wood Strengthens AI Chip Holdings With Nvidia And AMD Purchases, Reduces Palantir Position By Another $38.8 Million